Association between human chorionic gonadotropin (hCG) levels and adverse pregnancy outcomes: A systematic review and meta-analysis.

[1]  F. Shi,et al.  Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis , 2021, Frontiers in Endocrinology.

[2]  O. Christiansen,et al.  Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss , 2021, The Lancet.

[3]  Lizhang Chen,et al.  Adverse pregnancy outcomes among mothers with hypertensive disorders in pregnancy: A meta-analysis of cohort studies. , 2021, Pregnancy hypertension.

[4]  C. Redman,et al.  Syncytiotrophoblast stress in preeclampsia: the convergence point for multiple pathways. , 2020, American journal of obstetrics and gynecology.

[5]  C. Ying,et al.  Serum markers in quadruple screening associated with adverse pregnancy outcomes: A case-control study in China. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[6]  D. Lyell,et al.  Adverse Pregnancy Outcomes by Degree of Maternal Serum Analyte Elevation: A Retrospective Cohort Study , 2020, American Journal of Perinatology Reports.

[7]  M. Tarrahi,et al.  Assessment of β-human-derived chorionic gonadotrophic hormone (βhCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study , 2019, BMC pregnancy and childbirth.

[8]  V. Jaddoe,et al.  Human chorionic gonadotropin and risk of pre‐eclampsia: prospective population‐based cohort study , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  D. Krantz,et al.  Elevated maternal serum-free β-human chorionic gonadotropin (β-hCG) and reduced risk of spontaneous preterm delivery* , 2019, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[10]  E. Goto.  Meta‐regression analysis to evaluate relationships between maternal blood levels of placentation biomarkers and low delivery weight , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[11]  W. Long,et al.  Second-trimester Maternal Serum Screening Biomarkers in the Risk Assessment for Preeclampsia. , 2018, Annals of clinical and laboratory science.

[12]  P. Lumbiganon,et al.  The global epidemiology of preterm birth. , 2018, Best practice & research. Clinical obstetrics & gynaecology.

[13]  G. Guyatt,et al.  GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. , 2018, Journal of clinical epidemiology.

[14]  Z. Nachum,et al.  Predictive Value of Second-Trimester Biomarkers and Maternal Features for Adverse Pregnancy Outcomes , 2017, Fetal Diagnosis and Therapy.

[15]  K. Barnhart,et al.  Association of the very early rise of human chorionic gonadotropin with adverse outcomes in singleton pregnancies after in vitro fertilization. , 2016, Fertility and sterility.

[16]  T. Tongsong,et al.  Associations between maternal serum free beta human chorionic gonadotropin (β-hCG) levels and adverse pregnancy outcomes , 2016, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[17]  Yue Chen,et al.  Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies , 2015, BMC Pregnancy and Childbirth.

[18]  S. Bisai,et al.  Elevated serum βhCG and dyslipidemia in second trimester as predictors of subsequent Pregnancy Induced Hypertension. , 2015, Bangladesh Medical Research Council bulletin.

[19]  Lan-Lan Wang,et al.  Predictive Value of Free β-hCG Multiple of the Median for Women with Preeclampsia , 2015, Gynecologic and Obstetric Investigation.

[20]  G. Shaw,et al.  Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin , 2014, American Journal of Perinatology.

[21]  L. Waetjen,et al.  Population-based biomarker screening and the development of severe preeclampsia in California. , 2014, American journal of obstetrics and gynecology.

[22]  E. Moshier,et al.  Predictive value of combined serum biomarkers for adverse pregnancy outcomes. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[23]  B. Åsvold,et al.  Concentrations of human chorionic gonadotrophin in very early pregnancy and subsequent pre-eclampsia: a cohort study. , 2014, Human reproduction.

[24]  L. Vatten,et al.  Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case–control study , 2014, Acta obstetricia et gynecologica Scandinavica.

[25]  L. Nilas,et al.  First trimester pregnancy-associated plasma protein A and human chorionic gonadotropin-beta in early and late pre-eclampsia , 2014, Clinical chemistry and laboratory medicine.

[26]  D. Chou,et al.  Global and regional estimates of preeclampsia and eclampsia: a systematic review. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[27]  G. D'ottavio,et al.  First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. , 2012, Placenta.

[28]  R. Romero,et al.  The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. , 2011, American journal of obstetrics and gynecology.

[29]  G. Visser,et al.  First‐trimester serum PAPP‐A and fβ‐hCG concentrations and other maternal characteristics to establish logistic regression‐based predictive rules for adverse pregnancy outcome , 2011, Prenatal diagnosis.

[30]  I. Staboulidou,et al.  Reference range of birth weight with gestation and first‐trimester prediction of small‐for‐gestation neonates , 2011, Prenatal diagnosis.

[31]  E. Steegers,et al.  Pre-eclampsia , 2010, The Lancet.

[32]  Amanda J Lee,et al.  Inherited Predisposition to Spontaneous Preterm Delivery , 2010, Obstetrics and gynecology.

[33]  J. Foidart,et al.  Chorionic gonadotropin stimulation of angiogenesis and pericyte recruitment. , 2009, The Journal of clinical endocrinology and metabolism.

[34]  B. Sibai,et al.  Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. , 2006, American journal of obstetrics and gynecology.

[35]  D. Towner,et al.  Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. , 2006, American journal of obstetrics and gynecology.

[36]  K. Nicolaides,et al.  Prediction of pregnancy complications by first‐trimester maternal serum PAPP‐A and free β‐hCG and with second‐trimester uterine artery Doppler , 2005, Prenatal diagnosis.

[37]  F. Malone,et al.  Quad Screen as a Predictor of Adverse Pregnancy Outcome , 2005, Obstetrics and gynecology.

[38]  O. Erez,et al.  Increased maternal serum human chorionic gonadotropin concentrations are an independent risk factor for SGA in dichorionic twin gestations , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[39]  F. Malone,et al.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). , 2004, American journal of obstetrics and gynecology.

[40]  L. Dodds,et al.  Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. , 2003, American journal of obstetrics and gynecology.

[41]  A. Reiner,et al.  Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. , 2003, Human reproduction.

[42]  S. Roberts,et al.  Maternal serum activin, inhibin, human chorionic gonadotrophin and α‐fetoprotein as second trimester predictors of pre‐eclampsia , 2003, BJOG : an international journal of obstetrics and gynaecology.

[43]  H. Thaler,et al.  Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. , 2002, American journal of obstetrics and gynecology.

[44]  A. Orr-Urtreger,et al.  First Trimester Maternal Serum Free Human Chorionic Gonadotropin as a Predictor of Adverse Pregnancy Outcome , 2002, Fetal Diagnosis and Therapy.

[45]  Gordon C. S. Smith,et al.  Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. , 2002, The Journal of clinical endocrinology and metabolism.

[46]  J. Granger,et al.  Pathophysiology of pregnancy-induced hypertension. , 2001, American journal of hypertension.

[47]  A. Heikkilä,et al.  Elevated Maternal Serum hCG in the Second Trimester Increases Prematurity Rate and Need for Neonatal Intensive Care in Primiparous Preeclamptic Pregnancies , 2001 .

[48]  K. Nicolaides,et al.  First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications , 2000, BJOG : an international journal of obstetrics and gynaecology.

[49]  B. Sheu,et al.  Mid‐trimester β‐hCG levels incorporated in a multifactorial model for the prediction of severe pre‐eclampsia , 2000 .

[50]  C. J. Colby,et al.  Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. , 1999, The New England journal of medicine.

[51]  U. Ekblad,et al.  Prediction of pre‐eclampsia with maternal mid‐trimester total renin, inhibin A, AFP and free β‐hCG levels , 1999, Prenatal diagnosis.

[52]  R. Redline,et al.  Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. , 1999, American journal of clinical pathology.

[53]  A. Hartikainen,et al.  Midtrimester N‐terminal Proatrial Natriuretic Peptide, Free Beta hCG, and Alpha‐fetoprotein in Predicting Preeclampsia , 1998, Obstetrics and gynecology.

[54]  S. Fisher,et al.  Regulation of human placental development by oxygen tension. , 1997, Science.

[55]  T. Hung,et al.  Prediction of Adverse Perinatal Outcome By Maternal Serum Screening for Down Syndrome in an Asian Population , 1997, Obstetrics and gynecology.

[56]  F. Dunstan,et al.  All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median. , 1993, American journal of human genetics.

[57]  T. Khong,et al.  Defective haemochorial placentation as a cause of miscarriage; a preliminary study , 1987 .

[58]  Q. Zheng,et al.  Human chorionic gonadotropin, fetal sex and risk of hypertensive disorders of pregnancy: A nested case-control study. , 2016, Pregnancy hypertension.

[59]  F. Prefumo,et al.  Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. , 2008, Fertility and sterility.